Barclays lowered the firm’s price target on Centene (CNC) to $45 from $65 and keeps an Equal Weight rating on the shares after the company withdrew its 2025 guidance due to materially negative industry acuity trends in the ACA Marketplace and further pressure in Medicaid cost trends.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CNC:
- Centene’s Financial Outlook Challenged by Marketplace and Medicaid Trends, Hold Rating Issued
- Centene price target lowered to $65 from $90 at Cantor Fitzgerald
- Centene downgraded to Neutral from Overweight at JPMorgan
- Centene’s Financial Outlook: Hold Rating Amid Revenue Headwinds and Regulatory Uncertainties
- Centene downgraded to Neutral from Buy at UBS